|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
It is expected that the limited voting shares of the Company will begin trading under the new name, and that the Company's stock symbol will change from CXR to ADVZ, on or about December 3, 2018. "This is an exciting period for ADVANZ PHARMA, our stakeholders, and all our employees across the globe," said Graeme Duncan, the Company's Chief Executive Officer. "This new corporate identity, and the accompanying rebranding that we are working on, will help define ADVANZ PHARMA as a global pharmaceutical company that is determined to help innovate, shape and grow the specialty, off-patent sector.
MISSISSAUGA, ON , Nov. 14, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced its financial and operational results for the three and nine months ended September 30, 2018 . "Our third quarter results are consistent with our expectations," said Graeme Duncan , Chief Executive Officer of Concordia.
Concordia Healthcare (CXRXF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MISSISSAUGA, ON , Oct. 31, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its third quarter 2018 financial results before market open on Wednesday, November 14, 2018 .
"We believe that Maurice's extensive experience in the European pharmaceutical market will support Concordia's focus to acquire targeted products and companies in our core and proximate markets, and expand our product portfolio," said Graeme Duncan , Chief Executive Officer of Concordia. Mr. Chagnaud has more than 25 years of experience in the pharmaceutical sector including senior and leadership roles at Merck KgAa, Merck Generics, Teva, Lupin and Polpharma. Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries.